Shelly and Wayne chat with Dr. Michelle McMurry-Heath, Founder and CEO of BioTechquity Clinical, and Alan Minsk, Partner, Chair of the Food & Drug practice, and Co-Chair of the Life Sciences industry team at Arnall Golden Gregory LLP. You’ll hear their thoughts on the potential effects that FDA staffing cuts may have on drug and biologics approvals; how the current environment may affect investments in drug and biotech development; what companies can do to amid agency staffing shortages; how FDA can aim to include all demographics of patients in trials; and much more.

In our headlines segment, Shelly and Wayne delve into these major developments:

Pharma: Trump administration makes exception for pharmaceuticals amid rollout of tariffs

Devices: Industry continues to face the consequences of cutbacks at CDRH

Food: Food company completes FDA pre-market consultation for human food made with cultured pork fat cells

Cosmetics: PCPC executive issues statement on impact of Trump administration’s reciprocal tariffs on cosmetics and personal care products industry

In our Resource Links segment, we list key documents in our four core areas. To view these links, subscribe, or find out more information about our podcast, visit FDAWatch.net.

Want to be a sponsor, marketing partner, or guest, or provide feedback on the podcast? Email us at [email protected].

Music by Dvir Silver from Pixabay.